Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Athira Pharma, Inc. (ATHA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., August 10, 2023 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2023, and provided pipeline and business updates. “During the second quarter, we advanced and strengthened our pipeline ..."
07/07/2023 SC 13G/A BlackRock Inc. reports a 1.8% stake in Athira Pharma, Inc.
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term exposure data ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; Strongly supports development as a treatment for ALS Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
04/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/05/2023 ARS Form ARS - Annual Report to Security Holders:
04/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development of ATH-1105 as a potential clinical candidate for amyotrophic lateral sclerosis Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/30/2023 SC 13G/A FRANKLIN RESOURCES INC reports a 0% stake in Athira Pharma, Inc.
01/06/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "ATHIRA PHARMA, INC."
01/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/18/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/17/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk Updated study well powered for primary endpoint with addition of fewer than 150 patients Company targets completion of enrollment in mid-2023 and topline results in early 2024 Company to host live webcast today at 8:30 a.m. Eastern BOTHELL, Wash., Oct. 17, 2022 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, ...",
"LEARNINGS FROM ACT-AD INFORM STUDY DESIGN OPTIMIZATION"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
07/01/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/22/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/17/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/16/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/16/2022 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
05/12/2022 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
05/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/09/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy